According to published reports, Rani Therapeutics, has raised $39 million in Series D funding. Investors included GV, Novartis, Astra Zeneca, Cathay Ventures, Buttonwood, Crystal Horizon Investments, Pinemount Investments, the Pacific Venture Opportunity Fund and Bossa Nova Investments.

Rani Therapeutics has developed a novel approach for the oral delivery of large drug molecules including peptides, proteins and antibodies, which to date can only be delivered through injections.

The approach and technology for Rani Therapeutics was developed at InCube Labs, a multi-disciplinary life sciences R&D lab focused on developing breakthrough medical innovations.